| Although migraine represents the most common neurologic disorder, patients often do not receive the best acute phase therapy |
| The cornerstones of treatment continue to be represented by triptans and NSAIDs, with well-know related adverse effects |
| Gepants offer great promise, also targeting CGRP and ditans, 5-HT1F receptor agonists |
| Although therapies have been implemented in the last years, significant unmet treatment needs remain a reality in patients’ lives |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.